Your browser doesn't support javascript.
loading
Cross-Sectional Survey of Factors Contributing to COVID-19 Testing Hesitancy Among US Adults at Risk of Severe Outcomes from COVID-19.
Assaf, Annlouise R; Sidhu, Gurinder S; Soni, Apurv; Cappelleri, Joseph C; Draica, Florin; Herbert, Carly; Arham, Iqra; Bader, Mehnaz; Jimenez, Camille; Bois, Michael; Silvester, Eliza; Meservey, Jessica; Eng, Valerie; Nelson, Megan; Cai, Yong; Nangarlia, Aakansha; Tian, Zhiyi; Liu, Yanping; Watt, Stephen.
Afiliação
  • Assaf AR; Global Medical Patient Impact Assessment, Worldwide Medical and Safety, Pfizer Inc, Groton, CT, USA.
  • Sidhu GS; Brown University School of Public Health, Providence, RI, USA.
  • Soni A; US Medical Affairs, Pfizer Inc, 537 Alandele Ave, Los Angeles, CA, 90036, USA. gurinder.sidhu@pfizer.com.
  • Cappelleri JC; Program in Digital Medicine, University of Massachusetts, North Worcester, MA, USA.
  • Draica F; Biostatistics, Pfizer Inc, Groton, CT, USA.
  • Herbert C; US Medical Affairs, Pfizer Inc, New York, NY, USA.
  • Arham I; Program in Digital Medicine, University of Massachusetts, North Worcester, MA, USA.
  • Bader M; US Medical Affairs, Pfizer Inc, New York, NY, USA.
  • Jimenez C; Global Medical Patient Impact Assessment, Worldwide Medical and Safety, Pfizer Inc, New York, NY, USA.
  • Bois M; Global Medical Grants/Institute of Translational Equitable Medicine, Worldwide Medical and Safety, Pfizer Inc, New York, NY, USA.
  • Silvester E; US Medical Affairs, Pfizer Inc, New York, NY, USA.
  • Meservey J; Strategy Consulting, IQVIA, New York, NY, USA.
  • Eng V; Strategy Consulting, IQVIA, Boston, MA, USA.
  • Nelson M; Strategy Consulting, IQVIA, New York, NY, USA.
  • Cai Y; Strategy Consulting, IQVIA, Boston, MA, USA.
  • Nangarlia A; Advanced Analytics, IQVIA, Wayne, PA, USA.
  • Tian Z; Strategy Consulting, IQVIA, Boston, MA, USA.
  • Liu Y; Advanced Analytics, IQVIA, Wayne, PA, USA.
  • Watt S; Advanced Analytics, IQVIA, Wayne, PA, USA.
Infect Dis Ther ; 13(7): 1683-1701, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38869840
ABSTRACT

INTRODUCTION:

The United States Centers for Disease Control and Prevention (CDC) advises testing individuals for COVID-19 after exposure or if they display symptoms. However, a deeper understanding of demographic factors associated with testing hesitancy is necessary.

METHODS:

A US nationwide cross-sectional survey of adults with risk factors for developing severe COVID-19 ("high-risk" individuals) was conducted from August 18-September 5, 2023. Objectives included characterizing demographics and attitudes associated with COVID-19 testing. Inverse propensity weighting was used to weight the data to accurately reflect the high-risk adult US population as reflected in IQVIA medical claims data. We describe here the weighted results modeled to characterize demographic factors driving hesitancy.

RESULTS:

In the weighted sample of 5019 respondents at high risk for severe COVID-19, 58.2% were female, 37.8% were ≥ 65 years old, 77.1% were White, and 13.9% had a postgraduate degree. Overall, 67% were Non-testers (who indicated that they were unlikely or unsure of their likelihood of being tested within the next 6 months); these respondents were significantly more likely than Testers (who indicated a higher probability of testing within 6 months) to be female (60.2 vs. 54.1%; odds ratio [OR] [95% confidence interval (CI)], 1.3 [1.1‒1.4]), aged ≥ 65 years old (41.5 vs. 30.3%; OR [95% CI] compared with ages 18‒34 years, 0.6 [0.5‒0.7]), White (82.1 vs. 66.8%; OR [95% CI], 1.4 [1.1‒1.8]), and to identify as politically conservative (40.9 vs. 18.1%; OR [95% CI], 2.6 [2.3‒2.9]). In contrast, Testers were significantly more likely than Non-testers to have previous experience with COVID-19 testing, infection, or vaccination; greater knowledge regarding COVID-19 and testing; greater healthcare engagement; and concerns about COVID-19.

CONCLUSIONS:

Older, female, White, rural-dwelling, and politically conservative high-risk adults are the most likely individuals to experience COVID-19 testing hesitancy. Understanding these demographic factors will help guide strategies to improve US testing rates.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article